Aurobindo Pharma shares fell 3 percent, spooked by weak management commentary after Q3 earnings. Company sees a hyper competitive scenario in the US and says price pressure in US is expected in the first six months of the year.
The faceoff between the Infosys board and founders is more on governance than any strategic matters says, former CFO V Balakrishnan. \"The board is a big let-down in engaging with shareholders,\" he says in an interview to CNBC-TV18. He also clarifies it is not an issue between (Vishal) Sikka and the founders.
Note: Any changes made to your Portfolio today will be effective only in the next day's Networth mailer.
No comments:
Post a Comment